# RANKL-blockade for the Treatment of Erosive Osteoarthritis (OA) of Interphalangeal Finger Joints

> **NCT02771860** · PHASE2 · COMPLETED · sponsor: **University Hospital, Ghent** · enrollment: 100 (actual)

## Conditions studied

- Hand Osteoarthritis

## Interventions

- **DRUG:** denosumab
- **DRUG:** Placebo
- **DIETARY_SUPPLEMENT:** Calcium/Vit D supplementation

## Key facts

- **NCT ID:** NCT02771860
- **Lead sponsor:** University Hospital, Ghent
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2019-06-26
- **Final completion:** 2021-04-28
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2024-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02771860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02771860, "RANKL-blockade for the Treatment of Erosive Osteoarthritis (OA) of Interphalangeal Finger Joints". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02771860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*